deltatrials
Active Not Recruiting EARLY_PHASE1 INTERVENTIONAL 3-arm NCT06489015

Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials

An Open-label, Parallel-group Exploratory Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Recombinant Human Serum Albumin Injection in the Treatment of Mild to Moderate Alzheimer's Disease

Sponsor: Protgen Ltd

Conditions Alzheimer's Disease (AD)
Interventions Recombinant Human Serum Albumin
Updated 4 times since 2024 Last updated: Mar 8, 2026 Started: Jun 28, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Alzheimer's Disease (AD) and is currently ongoing. Protgen Ltd leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotRecruiting~Sep 2025 – ~Mar 2026 · 6 months · monthly snapshotRecruiting~Mar 2026 – present · 5 months · monthly snapshotActive Not Recruiting

Change History

4 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Sep 2025 — Mar 2026 [monthly]

    Recruiting EARLY_PHASE1

  3. Sep 2024 — Sep 2025 [monthly]

    Recruiting EARLY_PHASE1

  4. Aug 2024 — Sep 2024 [monthly]

    Recruiting EARLY_PHASE1

    First recorded

Jun 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Protgen Ltd
Data source: Protgen Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations